DK1276501T5 - Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi - Google Patents

Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi

Info

Publication number
DK1276501T5
DK1276501T5 DK01928938T DK01928938T DK1276501T5 DK 1276501 T5 DK1276501 T5 DK 1276501T5 DK 01928938 T DK01928938 T DK 01928938T DK 01928938 T DK01928938 T DK 01928938T DK 1276501 T5 DK1276501 T5 DK 1276501T5
Authority
DK
Denmark
Prior art keywords
photodynamic therapy
treating tumors
tumor
bearing
treating
Prior art date
Application number
DK01928938T
Other languages
Danish (da)
English (en)
Other versions
DK1276501T3 (da
Inventor
William C Fanslow Iii
Elaine K Thomas
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DK1276501T3 publication Critical patent/DK1276501T3/da
Application granted granted Critical
Publication of DK1276501T5 publication Critical patent/DK1276501T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01928938T 2000-04-25 2001-04-25 Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi DK1276501T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19954500P 2000-04-25 2000-04-25
PCT/US2001/013616 WO2001080888A2 (en) 2000-04-25 2001-04-25 Method for treatment of tumors using photodynamic therapy

Publications (2)

Publication Number Publication Date
DK1276501T3 DK1276501T3 (da) 2006-04-24
DK1276501T5 true DK1276501T5 (da) 2007-02-26

Family

ID=22737985

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01928938T DK1276501T5 (da) 2000-04-25 2001-04-25 Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi

Country Status (10)

Country Link
US (2) US20020041864A1 (es)
EP (1) EP1276501B9 (es)
AT (1) ATE313334T1 (es)
AU (2) AU5574001A (es)
CA (1) CA2407336A1 (es)
DE (1) DE60116075T4 (es)
DK (1) DK1276501T5 (es)
ES (1) ES2254408T4 (es)
PT (1) PT1276501E (es)
WO (1) WO2001080888A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2436233C (en) * 2001-01-30 2010-10-05 Altachem Pharma Ltd. Perylenequinones for use with immunotherapy agents
WO2002078766A2 (en) * 2001-04-02 2002-10-10 Genentech, Inc. Combination therapy
WO2003094767A1 (en) * 2002-03-25 2003-11-20 The General Hospital Corporation Methods of adjuvant photodynamic therapy to enhance radiation sensitization
WO2004092195A2 (en) * 2003-04-09 2004-10-28 Administrators Of The Tulane Educational Fund Dendritic cell binding proteins and uses thereof
GB2442915B (en) 2005-08-10 2009-12-16 Quest Pharmatech Inc Perylenequinone derivatives and uses thereof
US8454991B2 (en) * 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
US20100255080A1 (en) * 2009-04-02 2010-10-07 Sesvalia Usa, Llc Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
WO2012170072A1 (en) * 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス, インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
AU2019333175A1 (en) * 2018-08-29 2021-03-04 Shattuck Labs, Inc. FLT3L-based chimeric proteins
MX2021015643A (es) * 2019-06-17 2022-04-06 Enochian Biopharma Inc Vacuna alogénica contra el virus de inmunodeficiencia humana (vih) basada en linfocitos t para inducir la inmunidad celular y humoral.
IL308018A (en) 2021-04-30 2023-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for different MHC expression
AU2022292632A1 (en) * 2021-06-17 2023-12-21 Kalivir Immunotherapeutics, Inc. Tnfsf-l fusion proteins and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
ES2252732T3 (es) * 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
WO1995017202A1 (en) * 1993-12-23 1995-06-29 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing cd40
US6495129B1 (en) * 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
CN1172718C (zh) * 1995-10-04 2004-10-27 依默耐克斯有限公司 树突状细胞刺激因子
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US6146409A (en) * 1996-05-20 2000-11-14 Bergein F. Overholt Therapeutic methods and devices for irradiating columnar environments
AU705647B2 (en) * 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
WO2000051638A1 (en) * 1999-02-26 2000-09-08 Qlt Phototherapeutics Inc. Photodynamic therapy in combination with apoptosis inducing factors
US6756141B2 (en) * 2001-04-17 2004-06-29 Southwest Research Institute Three-electrode fuel cell

Also Published As

Publication number Publication date
ES2254408T4 (es) 2007-10-01
US20050129689A1 (en) 2005-06-16
PT1276501E (pt) 2006-05-31
US20020041864A1 (en) 2002-04-11
ES2254408T3 (es) 2006-06-16
AU5574001A (en) 2001-11-07
DK1276501T3 (da) 2006-04-24
EP1276501B1 (en) 2005-12-21
DE60116075D1 (de) 2006-01-26
DE60116075T2 (de) 2006-08-31
EP1276501B9 (en) 2007-01-24
WO2001080888A2 (en) 2001-11-01
ATE313334T1 (de) 2006-01-15
CA2407336A1 (en) 2001-11-01
DE60116075T4 (de) 2007-06-06
EP1276501A2 (en) 2003-01-22
WO2001080888A3 (en) 2002-08-29
AU2001255740B2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
DK1276501T3 (da) Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi
NO20022065L (no) Terapeutisk anvendelse
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
WO2001082961A3 (en) Methods for treating bone tumors
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
WO2005092073A3 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
WO2000057911A3 (en) Hapten-conjugated mammalian cells and methods of making and using thereof
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
TW200724158A (en) Combination therapy in the treatment of cancer
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
MXPA03005030A (es) Juego de reactivos inmunoterapeuticos para el tratamiento de tumores.
WO2005041860A3 (en) Stem cells for use in locating and targeting tumor cells
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
ATE245029T1 (de) Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor
UA88294C2 (ru) ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК